Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc.
First interim analysis included 95 participants with confirmed cases of COVID-19 Phase 3 study met statistical criteria with a vaccine efficacy of 94.5% (p
investors.modernatx.com
analysis: https://blogs.sciencemag.org/pipeline/archives/2020/11/16/modernas-vaccine-efficacy-readout
executive summary:
-95 total cases in the trial to date, split 90/5 between the control group and the vaccinated group.
-11 of 95 were severe infections: all 11 were in the controls and zero in the vaccine patients.
-“generally short lived” side effects noted: fatigue in 9.7% of patients, myalgia (muscle pain) in 8.9%, arthralgia (joint pain) in 5.2%, headache in 4.5%, and just “pain” in 4.1%.
2nd pres release: https://investors.modernatx.com/new...ounces-longer-shelf-life-its-covid-19-vaccine
-Moderna says that new stability testing shows that their vaccine remains stable for up to six months under standard freezer conditions, up to 30 days under standard refrigeration conditions, and up to 12 hours at room temperature. There’s no dilution or further handling at the point of administration. This is much more like what you want to see, as compared to the more demanding storage conditions that seem to be needed for the Pfizer candidate. This is how a lot of medicine (and food, for that matter) is already distributed and stored – our infrastructure is a lot more prepared for this.
right now the vaccine news is very good indeed.